当前位置: 首页 >> 检索结果
729. Risk markers for sudden unexpected death in epilepsy: an observational, prospective, multicentre cohort study.
作者: Manuela Ochoa-Urrea.;Xi Luo.;Laura Vilella.;Nuria Lacuey.;Shirin Jamal Omidi.;Norma J Hupp.;Blanca Talavera.;Johnson P Hampson.;M R Sandhya Rani.;Shiqiang Tao.;Xiaojin Li.;Christina Y Miyake.;Licong Cui.;Jaison S Hampson.;Ganne Chaitanya.;Yash Shashank Vakilna.;Rup K Sainju.;Daniel Friedman.;Maromi Nei.;Luke Allen.;Catherine A Scott.;Joana Oliveira.;Brian Gehlbach.;Stephan U Schuele.;Jennifer A Ogren.;Ronald M Harper.;Beate Diehl.;Lisa M Bateman.;George B Richerson.;Jose-Miguel Yamal.;Guo-Qiang Zhang.;Orrin Devinsky.;Samden D Lhatoo.
来源: Lancet. 2025年406卷10511期1497-1507页
Sudden unexpected death in epilepsy (SUDEP) is the leading cause of epilepsy-related mortality. Generalised-particularly nocturnal-convulsive seizures, longstanding epilepsy, and solitary living have been identified retrospectively as risk factors. No definitive electroclinical biomarkers have been prospectively ascertained. This study aimed to identify SUDEP risk markers using multimodality data with long-term follow-up.
730. Efficacy and safety of tirzepatide in children and adolescents with type 2 diabetes (SURPASS-PEDS): a randomised, double-blind, placebo-controlled, phase 3 trial.
作者: Tamara S Hannon.;Lily C Chao.;Margarita Barrientos-Pérez.;Karthik Chandrasekhar Pamidipati.;Laura Fernández Landó.;Clare J Lee.;Hiren Patel.;Brandon K Bergman.
来源: Lancet. 2025年406卷10511期1484-1496页
Current treatment options for youth-onset type 2 diabetes are limited and have demonstrated lower glycaemic efficacy than those for adult-onset type 2 diabetes. We aimed to assess the safety and efficacy of tirzepatide, a glucose-dependent insulinotropic polypeptide and GLP-1 receptor agonist, compared with placebo in youth-onset type 2 diabetes.
735. Osteoporosis.
Osteoporotic fractures are one of the most common and consequential diseases of advanced ageing and many antifracture therapies are widely available but largely underused. This Seminar presents an updated approach to osteoporosis consultation, drawing upon published evidence and collaborative expert opinion to place the data in a pragmatic and useful context for clinicians. New evidence on osteoporosis screening recommendations, fracture-risk assessment, intervention decisions, nutrition-based therapies, and antiresorptive and anabolic therapies are discussed, along with practical approaches to treatment in the oldest old, those with chronic kidney disease, and patients who continue to fracture despite therapy. Patient safety is emphasised by providing an overview of advice on safe discontinuation of denosumab in those who require it.
|